Company intelligence / Profile preview
Aisa Pharma, Inc.
Boston, Massachusetts, United Statesaisapharma.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Phase 2
01
Overview
Aisa Pharma has completed the first part of its Phase 2 RECONNOITER study for AISA-021 (cilnidipine) in patients with Secondary Raynaud's primarily due to Scleroderma, with the second part nearly complete. The FDA has granted orphan drug designation to AISA-021 for the treatment of Systemic Sclerosis.
- Therapeutic areas
- CardiovascularRheumatologyOphthalmologyEndocrinologyNeurology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
NIH (studying AISA-021 in Preclinical Screening for Pain Platform studies)
Beyond the preview
Go deeper on Aisa Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aisa Pharma, Inc..